Heart failure & cardiomyopathiesCohort study

HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes

JACC AdvPublished

  • prospective, multicenter DIABET-IC cohort

Authors' conclusion

In ambulatory adults with T2D, the HFpEF-ABA score showed moderate diagnostic discrimination for HFpEF and was associated with adverse clinical outcomes at follow-up.

Study context

Population
Outpatients with type 2 diabetes (T2D)outpatients with T2D
Participants
1,125 outpatients
Exposure
HFpEF-ABA score against HFpEF diagnosis based on the European Society of Cardiology guidelines criteria and confirmed by a cardiologist

Main finding

As reported in the abstract

HFpEF confirmed

HFpEF confirmed

190 participants (16.9%)

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)
Outcomes per 10-percentage-point increase in HFpEF probability · 3 years — Per 10-percentage-point increase in HFpEF probability · all-cause death1.34 (1.17–1.54)
Outcomes per 10-percentage-point increase in HFpEF probability · 3 years — Per 10-percentage-point increase in HFpEF probability · HF hospitalization1.16 (0.94–1.43)
Outcomes per 10-percentage-point increase in HFpEF probability · 3 years — Per 10-percentage-point increase in HFpEF probability · composite endpoint1.28 (1.14–1.44)

Outcomes with scores ≥75% · 3 years

ComparisonHR (95% CI)
Scores ≥75% · death2.40 (1.45–3.97)
Scores ≥75% · HF hospitalization2.51 (1.10–5.72)
Scores ≥75% · composite2.41 (1.55–3.73)

Diagnostic performance of HFpEF-ABA score

area under the receiver operating characteristic curve
0.75 (95% CI: 0.71-0.79)

Events over follow-up · 3 years

deaths
61
Heart failure (HF) hospitalizations
23

Original publication

HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes. JACC Adv. Published 2 September 2026. doi:10.1016/j.jacadv.2026.103196

Summarised from the published abstract; every number is checked against it